DS-9606a
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer, Metastatic Cancer, Germ Cell Tumor
Trial Timeline
May 31, 2022 → Feb 6, 2026
NCT ID
NCT05394675About DS-9606a
DS-9606a is a phase 1 stage product being developed by Daiichi Sankyo for Advanced Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05394675. Target conditions include Advanced Cancer, Metastatic Cancer, Germ Cell Tumor.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05394675 | Phase 1 | Terminated |
Competing Products
20 competing products in Advanced Cancer